PARP inhibitors
Breast Cancer Study Leads to New Susceptibility Gene, Potential Treatment Strategies
Researchers found risk variants in the DNA damage checkpoint gene ATRIP in a Polish founder population and linked the gene to breast cancer risk and HRD in other populations.
Results from a homologous recombination deficiency assay concordance study led by Friends of Cancer Research were presented at the AMP annual meeting.
Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay
Premium
The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.
Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan
Testing will be reimbursed for patients with early-stage breast cancer to guide adjuvant treatment with the PARP inhibitor Lynparza.
MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients
The bioinformatics startup will work with Macrogen Europe to develop an AI-based tool for analyzing WGS data to identify patients who should receive PARP inhibitors.